BioNexus Gene Lab (BGLC) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sera Prognostics is the larger company by market cap ($81.7 million vs $3.9 million), about 20.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BGLC | SERA |
|---|---|---|
| Share price | $1.34 | $2.07 |
| Market cap | $3.93M | $81.66M |
| 1-day change | +6.77% | +0.98% |
| YTD return | — | -29.83% |
| 1-year return | — | -36.31% |
| 5-year return | — | -80.92% |
| EPS (TTM) | $-1.26 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.89 | $3.95 |
| 52-week low | $1.07 | $1.56 |
| Distance from 52-week high | -77.24% | -47.59% |
| Average volume | 10.82K | 28.59K |
| Shares outstanding | 2.93M | 38.48M |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sera Prognostics is about 20.8 times larger than BioNexus Gene Lab by market value ($81.66M vs $3.93M).
BGLC vs SERA FAQ
Which is bigger, BioNexus Gene Lab or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $81.66M compared with $3.93M for BioNexus Gene Lab (BGLC).
Are BioNexus Gene Lab and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.